Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGEN1223 +/- Balstilimab in Advanced Solid Tumors
NCT04156100Phase 1Terminated
- Sponsor
- Agenus Inc.
- Start
- Dec 2019
- Primary completion
- Apr 2021
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of AGEN1223 in solid tumor (advanced stage) (2 arms), sponsored by Agenus Inc. Primary endpoints: Dose Limiting Toxicity and Treatment-Emergent Adverse Events. Started Dec 2019; status: terminated.
02
Drugs
AGEN1223
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04156100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04156100.